|
gptkbp:instanceOf
|
statin
hypolipidemic agent
|
|
gptkbp:approvedBy
|
1997
|
|
gptkbp:ATCCode
|
gptkb:C10AA06
|
|
gptkbp:brand
|
Baycol
Lipobay
|
|
gptkbp:CASNumber
|
145599-86-6
|
|
gptkbp:category
|
withdrawn drug
cholesterol-lowering agent
|
|
gptkbp:chemicalFormula
|
C26H34FNO5
|
|
gptkbp:contraindication
|
gptkb:liver_disease
pregnancy
breastfeeding
|
|
gptkbp:developedBy
|
gptkb:Bayer_AG
|
|
gptkbp:discoveredIn
|
1990s
|
|
gptkbp:drugClass
|
statin
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:has_stereochemistry
|
(3R,5S)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cerivastatin
|
|
gptkbp:interactsWith
|
gptkb:cyclosporine
gptkb:gemfibrozil
gptkb:fibrates
gptkb:erythromycin
gptkb:ketoconazole
niacin
itraconazole
|
|
gptkbp:IUPACName
|
(3R,5S,6E)-7-[4-(4-fluorophenyl)-2,6-dimethyl-5-(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
|
|
gptkbp:legalStatus
|
withdrawn
|
|
gptkbp:mechanismOfAction
|
HMG-CoA reductase inhibitor
|
|
gptkbp:MeSH_ID
|
C098727
|
|
gptkbp:metabolism
|
gptkb:CYP2C8
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
451.55 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:PubChem_CID
|
60854
CHEMBL1201212
|
|
gptkbp:retired
|
rhabdomyolysis risk
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
muscular dystrophy
rhabdomyolysis
|
|
gptkbp:UNII
|
N9YNS0M02X
|
|
gptkbp:usedFor
|
lowering cholesterol
|
|
gptkbp:withdrawn
|
2001
|
|
gptkbp:bfsParent
|
gptkb:CYP2C8
|
|
gptkbp:bfsLayer
|
6
|